The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
Reads0
Chats0
TLDR
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.About:
This article is published in Blood.The article was published on 2016-05-19 and is currently open access. It has received 5321 citations till now.read more
Citations
More filters
Journal ArticleDOI
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†.
Anne-Ségolène Cottereau,Anne-Ségolène Cottereau,Michel Meignan,Christophe Nioche,Nicolo Capobianco,Nicolo Capobianco,Jérôme Clerc,Loïc Chartier,Laetitia Vercellino,Olivier Casasnovas,Catherine Thieblemont,Irène Buvat +11 more
TL;DR: These two PET metrics, SDmax and MTV, are complementary to characterise the disease, reflecting the tumor burden and its spread, and appear promising for DLBCL baseline risk stratification.
Journal ArticleDOI
Artesunate shows potent anti-tumor activity in B-cell lymphoma
Thea Kristin Våtsveen,Thea Kristin Våtsveen,Marit Renée Myhre,Chloé B. Steen,Chloé B. Steen,Sébastien Wälchli,Sébastien Wälchli,Ole Christian Lingjærde,Baoyan Bai,Baoyan Bai,Pierre Dillard,Theodossis A. Theodossiou,Toril Holien,Anders Sundan,Else Marit Inderberg,Erlend B. Smeland,Erlend B. Smeland,June Helen Myklebust,June Helen Myklebust,Morten P. Oksvold,Morten P. Oksvold +20 more
TL;DR: Malaysia drug artesunate demonstrated potent apoptosis-inducing effects across a broad range of B-cell lymphoma cell lines in vitro, and a prominent anti-lymphoma activity in vivo, suggesting it to be a relevant drug for treatment ofB- cell lymphoma.
Journal ArticleDOI
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Anna Esteve-Arenys,Juan G. Valero,Aranzazu Chamorro-Jorganes,D. Gonzalez,Vanina Rodriguez,Ivan Dlouhy,Itziar Salaverria,Elias Campo,Dolors Colomer,A. Martinez,Grzegorz Rymkiewicz,Patricia Pérez-Galán,Armando López-Guillermo,Gaël Roué +13 more
TL;DR: It is demonstrated that single-agent ABT-199 efficiently displaces BAX from BCL-2 complexes but fails to maintain a significant antitumor activity over time in most MYC+/BCL2+DHL cell lines and primary cultures, as well as in a xenograft mouse model of the disease.
Journal ArticleDOI
How I treat breast implant-associated anaplastic large cell lymphoma
TL;DR: Recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network are shared.
Journal ArticleDOI
Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation
Janine Schmidt,Joan Enric Ramis-Zaldivar,Ferran Nadeu,Blanca Gonzalez-Farre,Alba Navarro,Caoimhe Egan,Ivonne A. Montes-Mojarro,Teresa Marafioti,José Cabeçadas,Jon van der Walt,Stefan Dojcinov,Andreas Rosenwald,German Ott,German Ott,Irina Bonzheim,Falko Fend,Elias Campo,Elaine S. Jaffe,Itziar Salaverria,Leticia Quintanilla-Martinez +19 more
TL;DR: TNFRSF14 and MAP2K1 mutations are the most frequent genetic alterations found in PTFL and occur independently in most cases, suggesting that both mutations might play an important role inPTFL lymphomagenesis.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente,Magda Pinyol,Víctor Quesada,Laura Conde,Gonzalo R. Ordóñez,Neus Villamor,Geòrgia Escaramís,Pedro Jares,Sílvia Beà,Marcos González-Díaz,Laia Bassaganyas,Tycho Baumann,Manel Juan,Mónica López-Guerra,Dolors Colomer,Jose M. C. Tubio,Cristina López,Alba Navarro,Cristian Tornador,Marta Aymerich,María Rozman,Jesús M. Hernández,Diana A. Puente,José M.P. Freije,Gloria Velasco,Ana Gutiérrez-Fernández,Dolors Costa,Anna Carrió,Sara Guijarro,Anna Enjuanes,Lluis Hernández,Jordi Yagüe,Pilar Nicolás,Carlos M. Romeo-Casabona,Heinz Himmelbauer,Ester Castillo,Juliane C. Dohm,Silvia de Sanjosé,Miguel A. Piris,Enrique de Alava,Jesús F. San Miguel,Romina Royo,Josep Lluís Gelpí,David Torrents,Modesto Orozco,David G. Pisano,Alfonso Valencia,Roderic Guigó,Mònica Bayés,Simon Heath,Marta Gut,Peter Klatt,John Marshall,Keiran Raine,Lucy Stebbings,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Ivo Gut,Armando López-Guillermo,Xavier Estivill,Emili Montserrat,Carlos López-Otín,Elias Campo +63 more
TL;DR: The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Related Papers (5)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more